Options: Relapsed and refractory non-Hodgkin's lymphoma

被引：0
|
作者：
Friedberg, Jonathan W. [1 ]
机构：
[1] Univ Rochester, Wilmot Canc Ctr, Rochester, NY USA
来源：
CANCER INVESTIGATION | 2007年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：36 / 37
页数：2
相关论文
共 50 条
  • [31] Concurrent chemotherapy and radiotherapy (CRT) in relapsed or refractory non-Hodgkin's lymphoma.
    Lapusan, S
    Ribrag, V
    Driss, B
    Vantelon, SM
    Fermé, C
    Bourhis, JH
    Girinsky, T
    [J]. BLOOD, 2001, 98 (11) : 243B - 244B
  • [32] Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma
    Leonard, JP
    Coleman, M
    Ketas, J
    Ashe, M
    Fiore, JM
    Furman, RR
    Niesvizky, R
    Shore, T
    Chadburn, A
    Horne, H
    Kovacs, J
    Ding, CL
    Wegener, WA
    Horak, ID
    Goldenberg, DM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 5044 - 5051
  • [33] Venetoclax (VEN) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
    Davids, Matthew Steven
    Roberts, Andrew Warwick
    Seymour, John Francis
    Wierda, William G.
    Puvvada, Soham D.
    Gressick, Lori A.
    Alter, Debbie
    Zhou, Lang
    Kim, Su Young
    Verdugo, Maria
    Gerecitano, John F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Activity of oxaliplatin in patients with relapsed and refractory non-Hodgkin lymphoma.
    Younes, A
    McLaughlin, P
    Pro, B
    Hagemeister, FB
    Fayad, L
    Romaguera, J
    [J]. BLOOD, 2002, 100 (11) : 296B - 296B
  • [35] VENETOCLAX (VEN) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL)
    Davids, M. S.
    Roberts, A. W.
    Seymour, J. F.
    Wierda, W. G.
    Puvvada, S. D.
    Gressick, L.
    Alter, D.
    Zhou, L.
    Kim, S. Y.
    Verdugo, M.
    Gerecitano, J. F.
    [J]. HAEMATOLOGICA, 2017, 102 : 218 - 219
  • [36] Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma
    Schmitt, Michael
    Trenschel, Rudolf
    Sayer, Herbert G.
    Schneider, Catarina
    Glass, Aenne
    Hilgendorf, Inken
    Treschl, Anne
    Junghanss, Christian
    Borchert, Kersten
    Koenigsmann, Michael
    Casper, Jochen
    Beelen, Dietrich W.
    Freund, Mathias
    Kahl, Christoph
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (05) : 773 - 782
  • [37] Venetoclax (VEN) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL).
    Davids, M.
    Roberts, A.
    Seymour, J.
    Wierda, W.
    Puvvada, S.
    Gressick, L.
    Alter, D.
    Zhou, L.
    Kim, S.
    Verdugo, M.
    Gerecitano, J.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 74 - 74
  • [38] Update on treatment options for non-Hodgkin's lymphoma
    Armitage, James O.
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2006, 7 : S6 - S6
  • [39] Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma
    Toukam, Marie
    Wuerthner, Jens
    Havenith, Karin
    Hamadani, Mehdi
    Caimi, Paolo F.
    Kopotsha, Tim
    Cruz, Hans G.
    Boni, Joseph P.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (01) : 13 - 24
  • [40] Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma
    Marie Toukam
    Jens Wuerthner
    Karin Havenith
    Mehdi Hamadani
    Paolo F. Caimi
    Tim Kopotsha
    Hans G. Cruz
    Joseph P. Boni
    [J]. Cancer Chemotherapy and Pharmacology, 2023, 91 : 13 - 24
12345